公开(公告)号：US20020169125A1

公开(公告)日：2002-11-14

申请号：US10101487

申请日：2002-03-20

Applicant: CELL THERAPEUTICS, INC.

Inventor： David W. Leung ,  Philip A. Bergman ,  Alan Lofquist ,  Gregory E. Pietz ,  Christopher K. Tompkins ,  David W. Waggoner JR.

IPC: A61K038/17 ,  A61K038/18 ,  A61K038/19 ,  A61K038/20 ,  A61K038/21

CPC classification number: C07K7/06 ,  A61K47/645 ,  C07K7/08 ,  C07K14/001 ,  C07K2319/00

Abstract: A polyanionic polymer can improve the bioactivity and water-solubility properties of a drug to which it is joined. The inventive method provides a monodispersed preparation of a recombinantly-produced polyanionic polymer that can be easily manipulated, such as lengthened. An active moiety may be chemically or recombinantly joined to a polyanionic polymer to increase its biological half-life and/or solubility. The instant invention also provides a method for targeting the delivery of a polyanionic polymer conjugate or fusion protein to a specific cell type or tissue.

Abstract translation: 聚阴离子聚合物可以改善与其结合的药物的生物活性和水溶性。 本发明的方法提供可以容易地操作的重组生产的聚阴离子聚合物的单分散制剂，例如延长的。 活性部分可以化学或重组连接到聚阴离子聚合物以增加其生物半衰期和/或溶解度。 本发明还提供了将聚阴离子聚合物缀合物或融合蛋白递送至特定细胞类型或组织的方法。

公开(公告)号：US20020107269A1

公开(公告)日：2002-08-08

申请号：US09984889

申请日：2001-10-31

Applicant: CELL THERAPEUTICS, INC.

Inventor： Lynn Bonham ,  J. Peter Klein ,  Robert E. Finney ,  David M. Hollenback ,  Scott A. Shaffer ,  Norina M. Tang ,  Thayer H. White ,  David W. Leung

IPC: A61K031/428 ,  A61K031/423 ,  A61K031/4184 ,  C07D277/60 ,  C07D263/56

CPC classification number: C07D263/57 ,  C07D235/18 ,  C07D277/66

Abstract: The invention relates to benzoxazoles and the use thereof to inhibit lysophosphatidic acid acyltransferase null (LPAAT-null) activity. The invention further relates to methods of treating cancer using said benzoxazoles. The invention also relates to methods for screening for LPAAT-null activity.

Abstract translation: 本发明涉及苯并恶唑及其用于抑制溶血磷脂酰基转移酶β（LPAAT-β）活性的用途。 本发明还涉及使用所述苯并恶唑治疗癌症的方法。 本发明还涉及用于筛选LPAAT-β活性的方法。

公开(公告)号：US20040086996A1

公开(公告)日：2004-05-06

申请号：US10667464

申请日：2003-09-23

Applicant: CELL THERAPEUTICS, INC.

Inventor： David W. Leung ,  Daniel Adourel ,  David Hollenback

IPC: C12N009/10

CPC classification number: C12N9/1029

Abstract: Polypeptides are obtained, for example, via expression of encoding cDNA sequences, that have the activity of the enzyme lysophosphatidic acid acyltransferase (LPAAT), also known as 1-acyl sn-glycerol-3-phosphate acyltransferase.

Abstract translation: 多肽例如通过编码cDNA序列的表达获得，其具有酶溶血磷脂酸酰基转移酶（LPAAT）的活性，也称为1-酰基sn-甘油-3-磷酸酰基转移酶。

公开(公告)号：US20020168747A1

公开(公告)日：2002-11-14

申请号：US10136517

申请日：2002-05-02

Applicant: CELL THERAPEUTICS, INC.

Inventor： David W. Leung

IPC: C12N009/20 ,  C07H021/04 ,  C12P021/02 ,  C12N005/06

CPC classification number: C12N9/1241 ,  C12Y207/07041

Abstract: There is disclosed cDNA sequences and polypeptides having the enzyme CDP-diacylglycerol synthase (CDS) activity. CDS is also known as CTP:phosphatidate cytidylyltransferase. There is further disclosed methods for isolation and production of polypeptides involved in phosphatidic acid metabolism and signaling in mammalian cells, in particular, the production of purified forms of CDS.

Abstract translation: 公开了具有酶CDP-二酰基甘油合成酶（CDS）活性的cDNA序列和多肽。 CDS也称为CTP：磷脂酰胞苷酰转移酶。 进一步公开了分离和产生参与哺乳动物细胞中磷脂酸代谢和信号传导的多肽的方法，特别是生产纯化形式的CDS。

公开(公告)号：US20040043465A1

公开(公告)日：2004-03-04

申请号：US10667494

申请日：2003-09-23

Applicant: CELL THERAPEUTICS, INC.

Inventor： David W. Leung ,  Daniel Adourel ,  David Hollenback

IPC: C12N009/10 ,  C07H021/04

CPC classification number: C12N9/1029

Abstract: Polypeptides are obtained, for example, via expression of encoding cDNA sequences, that have the activity of the enzyme lysophosphatidic acid acyltransferase (LPAAT), also known as 1-acyl sn-glycerol-3-phosphate acyltransferase.

公开(公告)号：US20040162288A1

公开(公告)日：2004-08-19

申请号：US10712900

申请日：2003-11-13

Applicant: Cell Therapeutics, Inc.

Inventor： Baoqing Gong ,  John Tulinsky ,  Lynn Bonham ,  J. Peter Klein ,  Robert E. Finney ,  David M. Hollenback ,  Scott A. Shaffer ,  Norina M. Tang ,  Thayer H. White ,  David W. Leung

IPC: A61K031/5377 ,  A61K031/53

CPC classification number: C07D251/70 ,  C07D251/50 ,  C07D251/52 ,  C07D251/54 ,  C07D251/58

Abstract: The invention relates to triazines and the use thereof to inhibit lysophosphatidic acid acyltransferase null (LPAAT-null) activity. The invention further relates to methods of treating cancer using said triazines. The invention also relates to methods for screening for LPAAT-null activity.

Abstract translation: 本发明涉及三嗪及其用于抑制溶血磷脂酰基转移酶β（LPAAT-β）活性的用途。 本发明还涉及使用所述三嗪治疗癌症的方法。 本发明还涉及用于筛选LPAAT-β活性的方法。

公开(公告)号：US20040082049A1

公开(公告)日：2004-04-29

申请号：US10667462

申请日：2003-09-23

Applicant: CELL THERAPEUTICS, INC.

Inventor： David W. Leung ,  Daniel Adourel ,  David Hollenback

IPC: C12N009/10

CPC classification number: C12N9/1029

Abstract: Polypeptides are obtained, for example, via expression of encoding cDNA sequences, that have the activity of the enzyme lysophosphatidic acid acyltransferase (LPAAT), also known as 1-acyl sn-glycerol-3-phosphate acyltransferase.

公开(公告)号：US20020103195A1

公开(公告)日：2002-08-01

申请号：US09984888

申请日：2001-10-31

Applicant: CELL THERAPEUTICS,INC.

Inventor： Lynn Bonham ,  J. Peter Klein ,  Robert E. Finney ,  David M. Hollenback ,  Scott A. Shaffer ,  Norina M. Tang ,  Thayer H. White ,  David W. Leung

IPC: A61K031/5377 ,  A61K031/53 ,  C07D413/14 ,  C07D43/14

CPC classification number: C07D251/70 ,  C07D251/50 ,  C07D251/52 ,  C07D251/54 ,  C07D251/58

Abstract: The invention relates to triazines and the use thereof to inhibit lysophosphatidic acid acyltransferase null (LPAAT-null) activity. The invention further relates to methods of treating cancer using said triazines. The invention also relates to methods for screening for LPAAT-null activity.

Abstract translation: 本发明涉及三嗪及其用于抑制溶血磷脂酰基转移酶β（LPAAT-β）活性的用途。 本发明还涉及使用所述三嗪治疗癌症的方法。 本发明还涉及用于筛选LPAAT-β活性的方法。